Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024. Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA. Maria Törnsén, President North America, will be moderating a panel, entitled “Partnering in the rare disease space – industry perspective”.
LSX World Congress, Monday, April 29, 2024, in London. Maria Törnsén, President North America, will participate in a panel discussion entitled “Commercial Models of The Future and How the Biopharma Launch Landscape Is Changing: Expert Panel Discussion”.
The same day, Renée Aguiar-Lucander, CEO, will participate in a panel discussion entitled “The Inflation Reduction Act and its Potential Impact on EU Biotech & Pharma Companies: Demystifying the Future”.
Additionally, Calliditas’ Group General Counsel, Brian Gorman, will participate in a panel discussion entitled “Importance of IP Due-Diligence in Deals Within the US”.
One-on-one meetings with management will be available.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel : +46 76 403 35 43, Email : asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on April 9, 2023, at 13.00 p.m. CET.